BioCentury
ARTICLE | Company News

Caelus investment among J&J's microbiome deals

February 2, 2017 11:34 PM UTC

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson (NYSE:JNJ) announced three microbiome-related deals Thursday, including an equity investment in cardiometabolic company Caelus Health (Amsterdam, the Netherlands).

J&J’s Johnson & Johnson Innovation-JJDC Inc. venture arm led Caelus' EUR 2.5 million ($2.7 million) series A round. The start-up will join J&J’s Belgium-based JLINX incubator and will gain access to JHMI’s computational resources for use in identifying potential microbiome-based therapies. Caelus’ lead candidate, CP-001, is in Phase I testing to treat metabolic syndrome. It is an oral Eubacterium hallii-based microbiome therapeutic...